Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Carbetocin→

Carbetocin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
37025-55-1
Molecular formula
C45H69N11O12S
Molecular weight
988.2 g/mol
Drug class
Long-acting oxytocin-receptor agonistuterotonic peptide analogue
Mechanism of action
Selectively binds oxytocin receptors in uterine smooth muscle, stimulates rhythmic contractions, increases the frequency of existing contractions and raises uterine tone. The effect is longer lasting than oxytocin.
Indications / reported uses
  • Prevention of postpartum haemorrhage due to uterine atony following caesarean section or vaginal delivery; a single dose is administered only after delivery under specialist obstetric supervision. It must not be used to induce labour.

Sources: UK SmPC — Pabal 100 micrograms/ml solution for injection · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Carbetocin Environmental Risk Assessment (ERA) (the Carbetocin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.